Vanda Pharmaceuticals Inc.
VNDA
$4.92
-$0.10-1.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -324.23% | -502.19% | -611.38% | -104.67% | -3,986.13% |
| Total Depreciation and Amortization | 4.37% | 2.54% | -10.84% | 70.38% | 239.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -87.43% | -2,391.49% | -248.11% | 107.61% | -139.46% |
| Change in Net Operating Assets | 15.71% | 432.15% | -127.43% | -74.54% | -42.22% |
| Cash from Operations | -116.90% | -120.15% | -537.93% | 51.31% | -611.27% |
| Capital Expenditure | 0.00% | 81.68% | 83.92% | 99.79% | -570.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 76.16% | -9.84% | 385.94% | -92.64% | -65.44% |
| Cash from Investing | 77.18% | -0.05% | 340.98% | 109.12% | -65.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -364.71% | 993.33% | 450.00% | -234.67% | 155.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -346.29% | -38.77% | 188.91% | 103.84% | -107.41% |